Cosmos Holdings Inc. - COSM STOCK NEWS

Cosmos Health (NASDAQ:COSM) has completed Phase I of upgrades to its manufacturing capabilities at its subsidiary, Cana Laboratories. The company has invested $5.5 million in upgrading its 54,000-square-foot Athens facility, positioning it to generate over $10 million in recurring annual gross profit at full capacity by the end of 2025. Cosmos Health has entered into contract manufacturing agreements with Provident Pharmaceuticals and Humacology to produce 5,520,000 units of medicines and CBD products, occupying less than 20% of existing capacity. The company is actively pursuing additional contracts and evaluating opportunities for a Phase II expansion plan to further enhance capacity and profitability potential.

Cosmos Health (NASDAQ:COSM) announced that its subsidiary, Cana Laboratories, has secured additional contract manufacturing agreements with Provident Pharmaceuticals. The new orders include:

• 408,000 units of MIOREL for muscle spasms
• 222,000 units of CALCIFOLIN for nucleic acid synthesis
• 72,000 units of DEXA-DOSE for anti-inflammatory purposes

These orders, combined with a previously announced contract for 4.32 million units of DE3-SOLE, bring the total order book with Provident to 5.02 million units. CEO Greg Siokas expressed enthusiasm for scaling up Cana's contract manufacturing division, anticipating stable, high-margin cash flows for Cosmos Health.

Cosmos Health Inc. (NASDAQ:COSM) has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company received a notification letter from Nasdaq on July 19, 2024, confirming that it had achieved a closing bid price of $1.00 or greater for ten consecutive business days from July 5 to July 18, 2024. This compliance was achieved organically without a reverse stock split. Cosmos Health is a diversified, vertically integrated global healthcare group involved in R&D, pharmaceutical and nutraceutical brands, healthcare product distribution, and telehealth services.

Cosmos Health (NASDAQ:COSM) announced the successful completion of the pilot production and scale-up phases for its weight management solution, CCX0722, a biocompatible hydrogel. These milestones mark the end of the development phase, following earlier project updates such as the initiation in November 2022, the completion of the second phase in June 2023, and a European patent filing in December 2023. The hydrogel exhibited a swelling ratio of over 100 g/g, a significant improvement confirmed during the scale-up process. Cosmos Health anticipates completing additional key steps by the end of 2024, including clinical trials and preparing CCX0722 for classification as a Type III medical device. The global weight management market, valued at $142.58 billion in 2022, is projected to reach $298.66 billion by 2030, driven by rising obesity rates. CEO Greg Siokas expressed enthusiasm for entering this lucrative market, while R&D Advisory Board member Dr. Panagiotis Zoumpoulakis highlighted the commitment to advancing healthcare solutions.

Cosmos Health's subsidiary, Cana Laboratories, has signed a contract manufacturing agreement with Australian wellness company Humacology. The agreement entails producing up to 500,000 units of CBD products annually. This is the second major deal for Cana in a week, following a similar agreement with Provident Pharmaceuticals for 4.32 million units of DE3-SOLE. Humacology, known for high-quality CBD therapies and medicinal cannabis, is expanding globally and has chosen Cana for its manufacturing needs. CEO of Cosmos, Greg Siokas, highlighted the company's rapid growth in high-margin contract manufacturing and hinted at more upcoming agreements.

Cosmos Health has enhanced and expanded its strategic collaboration with C.A. Papaellinas Group in Cyprus. The collaboration, originally announced on September 20, 2023, has led to the sale of 68,000 units of Sky Premium Life products. The company now projects sales will more than double to 150,000 units within the next 12 months due to increased market penetration.

Papaellinas, a leading distributor in Cyprus, represents brands like Panadol, Sensodyne, and Adidas, and operates retail chains including Holland & Barrett. The expansion aims to increase sales and explore additional opportunities beyond the current product line. CEO Greg Siokas expressed satisfaction with the partnership and the positive market reception.

Cosmos Health's subsidiary, Cana Laboratories, has finalized significant facility upgrades, enhancing its production capabilities.

In tandem, Cana secured a contract manufacturing agreement with Provident Pharmaceuticals to produce 4.32 million vials of DE3-SOLE, a key pharmaceutical product. This strategic partnership is expected to bolster Cosmos Health's market position and revenue streams.

The facility upgrades aim to improve operational efficiency and meet increasing demand, while the large-scale contract underscores Cana's manufacturing prowess and Provident's trust in their capabilities.

The agreement reflects a significant milestone for Cosmos Health, potentially driving robust financial growth and enhancing shareholder value.

Cosmos Health announced a distribution agreement with ZENDON for its Sky Premium Life nutraceutical products in Slovakia, Hungary, Poland, and Czechia. The agreement will leverage Zendon's existing partnerships with leading pharmacy and retail chains, providing access to over 6,000 stores. This strategic move aims to gain market share in Central and Eastern Europe, with major partners including Dr. Max, Teta Drogerie, and Rossmann. CEO Greg Siokas highlighted the company's commitment to expanding its global footprint and achieving sustained profitability.

Cosmos Health announced an exclusive distribution agreement with Pharmalink to market its Sky Premium Life nutraceuticals in the UAE. Pharmalink, a leading UAE healthcare organization, will manage sales, marketing, logistics, and distribution functions. Cosmos has received an initial order of 130,000 units and forecasts sales of over 500,000 units in the first year and more than 3 million units over the next five years. Pharmalink's CEO, Dr. Abdul Rauf Jabour, and Cosmos Health's CEO, Greg Siokas, expressed optimism about the partnership's potential to penetrate the UAE nutritional supplements market.